Prof. Dr. Dr. Rolf G. Werner is Honorary Senator of University of Tuebingen, teaching Industrial Biotechnology. He is member of the Advisory Board of Navigo Proteins GmbH in Halle/Saale. After his PhD at University Tübingen he spent more than three years in academia at Max Planck Institute for Molecular Genetics, Berlin, Germany, and at the Massachusetts Institute for Technology, Cambridge, USA. He has more than 35 years industry experience at Boehringer Ingelheim in top leading positions. Rolf was responsible for the development and registration of the first genetically engineered protein therapeutic from mammalian cell culture: tissue plasminogen activator for myocardial infarction and stroke. More than 20 therapeutic proteins and monoclonal antibodies have been developed, manufactured and regulatory approved under his responsibility and direction. Under his supervision, processes for viral therapeutics and vaccines have been developed. He is consulting with biopharmaceutical, viral therapeutic and vaccine companies in Europe and Asia in all aspects of research and production technologies. His achievements are recognized by the Prize of the City of Vienna, Austria, for outstanding scientific work, as well as from the Hangzhou Government, China, as Hangzhou Qian Jiang Distinguished Expert in Biotechnology.